Medical Design Sourcing

GlucoTrack

Glucotrack has positive data for implantable continuous blood glucose monitor

Glucotrack (Nasdaq:GCK) announced today that it completed the first preclinical study of its implantable continuous blood glucose monitor (CBGM).

Rutherford, New Jersey-based Glucotrack aimed to assess the implant technique and device safety in the study. Additionally, the study used a small sample size of sensors to determine device functionality.

Despite no intent to conduct an accuracy study, the company reported a mean absolute relative difference (MARD) of 8.1% at day 30 and 4.5% at day 60. Glucotrack reported no significant adverse events.

Get the full story at our sister site, Drug Delivery Business News.

GlucoTrack transitions strategic focus to long-term implantable CGM

Glucotrack (Nasdaq:GCTK) President and CEO Paul V. Goode today issued a statement to shareholders outlining strategic changes.

Goode’s letter to shareholders announced a redefined strategic direction. The company wants to move closer to becoming a leader in the diabetes market.

According to Goode, the diabetes market has undergone a transformation over recent years. He attributed that to the growth of continuous glucose monitoring (CGM), shifting focus from point-in-time glucose monitoring. With that market shift, Glucotrack intends to shift its own focus from non-invasive, non-continuous glucose monitoring. It now aims to bolster the CGM technology within its portfolio.

Get the full story at our sister site, Drug Delivery Business News.

Glucotrack tabs former Medtronic veteran for a board director spot

New Glucotrack board member Erin Carter. [Image courtesy of Erin Carter on LinkedIn]Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee.

Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately.

Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes.

Get the full story at our sister site, Drug Delivery Business News.

Implantable CGM maker Glucotrack names new VP of marketing

New Glucotrack VP of Marketing Drinda Benjamin. [Image from Drinda Benjamin on LinkedIn]Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing.

Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device.

Benjamin brings more than 20 years of experience in life sciences to Glucotrack, with focus on commercializing health technology. She has past experiences in product development, strategic marketing and more in the diabetes space. That includes work with blood glucose monitoring, CGM, insulin delivery and closed-loop systems.

Get the full story at our sister site, Drug Delivery Business News.

Feasibility study backs Glucotrack implantable CGM

Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM).

Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing a long-term continuous glucose monitor (CGM) for people with type 1 diabetes.

With an aim to commercialize a long-term sensor, Glucotrack hopes its offering will have no requirement for an additional wearable component. The company also hopes for a once-only calibration for the platform. It believes these can serve as key differentiators in the CGM market.

Get the full story at our sister site, Drug Delivery Business News.

GlucoTrack hires former Dexcom scientist as VP of sensor technology

GlucoTrack (Nasdaq:GCTK) announced today that it appointed Mark Tapsak as its vice president of sensor technology.

Tapsak, a veteran of more than 25 years in the diabetes industry, joins the company, effective immediately. His experience includes time spent as a medical device research scientist. He focused on polymer synthesis, polymer characterization, medical device design and intellectual property.

Get the full story at our sister site, Drug Delivery Business News.

GlucoTrack to begin R&D for new long-term CGM

GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with a R&D program for a long-term continuous glucose monitor (CGM).

Rutherford, New Jersey-based GlucoTrack said it recently required related IP. It now intends to develop a long-term, implantable glucose management platform for the type 1 diabetes market.

Get the full story at our sister site, Drug Delivery Business News.

GlucoTrack provides positive update on next-gen glucose monitor

GlucoTrack (Nasdaq:GCTK) announced today that its second-generation glucose monitor device has shown promising results in analyses.

Rutherford, New Jersey-based GlucoTrack — formerly known as Integrity Applications (Nasdaq:IGAP) — earlier this year completed lab testing of the non-invasive GlucoTrack 2.0 clinical prototype system and has observed better-than-expected accuracy and performance with the technology.

Get the full story at our sister site, Drug Delivery Business News.

Integrity Applications changes company name to GlucoTrack

Integrity Applications (Nasdaq:IGAP) announced today that it completed the change of its corporate name to GlucoTrack.

Rutherford, New Jersey-based GlucoTrack confirmed the change of its ticker symbol on the Nasdaq capital market to “GCTK,” which was made effective at the commencement of trading today, March 14, 2022.

Get the full story at our sister site, Drug Delivery Business News.